Former Teva and Actavis generics chief Siggi Olafsson has been appointed as chief executive officer of Hikma. He succeeds chairman and chief executive Said Darwazah, who will continue to chair Hikma’s board of directors, taking on the title of executive chairman.
Former Teva and Actavis generics chief Siggi Olafsson has been appointed as chief executive officer of Hikma. He succeeds chairman and chief executive Said Darwazah, who will continue to chair Hikma’s board of directors, taking on the title of executive chairman.
As chief, Hikma noted, Olafsson would be responsible for the “effective development and execution of Hikma’s corporate strategy, focusing on...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
